Morning Movers 02/07: (SATC) (BMTI) (CSTR) (MNI) Higher; (ASTX) (ACHN) (BVSN) Lower
Down)
Satcon Technology Corporation (NASDAQ: SATC) 24.3% HIGHER; announced a partnership with Great Wall Computer Company Limited. The partnership will position Satcon to capitalize on the estimated 14GW of utility scale projects under development, fueled by the country’s Feed-In Tariff program. Of the 14GW of identified non-residential solar projects in development in China today, the majority are expected to be developed by China State Owned Entities.
Astex Pharmaceuticals, Inc. (Nasdaq: ASTX) 19% LOWER; according to FDA briefing documents from this morning, a study for dacogen failed to demonstrate benefit based on statistical interpretation.
BioMimetic Therapeutics (Nasdaq: BMTI) 18% HIGHER; as highlighted by a Collins Stewart note this morning, the company announced 6-month results of its 30-patient Canadian Augment Rotator Cuff Graft trial last night. A Collins Stewart analyst called the pilot study positive and said it could create another sizable opportunity for the company.
Coinstar, Inc. (NASDAQ: CSTR) 17.6% HIGHER; reported Q4 EPS of $1.00, $0.36 better than the analyst estimate of $0.64. Revenue for the quarter came in at $520.5 million versus the consensus estimate of $498.09 million. Sees Q1 core EPS of 76-91 cents, which compares to the Street estimate of 86 cents. Sees sales of $530-$555 million, which compares to the Street estimate of $514.5 million. Sees FY12 EPS $3.80-$4.30 on sales of $2.08-$2.25 billion. The Street is currently expecting EPS of $3.86 on sales of $2.17 billion. Also announced it will acquire the assets of NCR's (NYSE: NCR) DVD business. Terms were not disclosed.
Achillion Pharmaceuticals (NASDAQ: ACHN) 16.7% LOWER; BofA/Merrill Lynch downgraded the stock from Buy to Underperform.
McClatchy Co. (NYSE: MNI) 16.5% HIGHER; reported Q4 EPS of $0.49, $0.09 better than the analyst estimate of $0.40. Revenue for the quarter came in at $351.4 million versus the consensus estimate of $347.8 million.
BroadVision (Nasdaq: BVSN) 15.8% LOWER; after rallying nearly 13 percent at the open, the stock tumbled by nearly 30 percent on no apparent news. Volume spiked sharply as downside intensified.
Standard Pacific Corp. (NYSE: SPF) 13.8% HIGHER; reported Q4 EPS of $0.04, $0.02 better than the analyst estimate of $0.02. Revenue for the quarter came in at $293.2 million versus the consensus estimate of $275.21 million.
Cambrex Corp. (NYSE: CBM) 13.7% LOWER; reported Q4 EPS of $0.10, $0.02 worse than the analyst estimate of $0.12. Revenue for the quarter came in at $67.1 million versus the consensus estimate of $64.85 million. Sees FY2012 EBITDA of $47-$53 million. Sees FY2012 revenue of growth of 2-6%, versus the consensus of 5%.
Biosante Pharma (Nasdaq: BPAX) 12.4% LOWER; investors taking profits today following six straight sessions of upside. The stock surged nearly 42 percent yesterday following a bullish SeekingAlpha article. The stock is back under $1 today.
K12, Inc. (NYSE: LRN) 12.3% LOWER; reported Q2 EPS of $0.11, $0.15 worse than the analyst estimate of $0.26. Revenue for the quarter came in at $166.5 million versus the consensus estimate of $170.16 million. K12, Inc. sees FY2012 revenue of $680-$690 million, versus the consensus of $693.4 million.
RTI Int'l Metals, Inc. (NYSE: RTI) 11.6% LOWER; reported Q4 EPS of $0.00, $0.10 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $141.9 million versus the consensus estimate of $137.81 million.
Solarwinds (NYSE: SWI) 10.2% HIGHER; reported Q4 EPS of $0.29, $0.04 better than the analyst estimate of $0.25. Revenue for the quarter came in at $55.6 million versus the consensus estimate of $53.87 million. Sees Q1 2012 EPS of $0.24-$0.25, versus the consensus of $0.25. Sees Q1 2012 revenue of $55.5-$56.7 million, versus the consensus of $54.44 million. Sees FY2012 EPS of $1.10-$1.15, versus the consensus of $1.13. Sees FY2012 revenue of $245-$255 million, versus the consensus of $242.96 million.
Regal-Beloit Corp. (NYSE: RBC) 9.9% HIGHER; reported Q4 EPS of $0.93, $0.23 better than the analyst estimate of $0.70. Revenue for the quarter came in at $727 million versus the consensus estimate of $721.59 million.
Vishay Intertechnology, Inc. (NYSE: VSH) 9.9% LOWER; reported Q4 EPS of $0.15, $0.04 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $551 million versus the consensus estimate of $570.63 million. For Q1, Vishay sees similar revenues as in quarter four 2011 at a slightly improved gross margin.
Threshold Pharma (Nasdaq: THLD) 9.8% LOWER; traders finally taking profits following a 130 percent rise on Friday and another 13 percent surge yesterday. The stock jumped following news of a TH-302 commercialization agreement with Merck.
PHH Corp. (NYSE: PHH) 9% HIGHER; reported Q4 core EPS of $0.98, $0.25 better than the analyst estimate of $0.73. Revenue for the quarter came in at $649 million versus the consensus estimate of $684.7 million.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Astex Pharmaceuticals, Inc. (Nasdaq: ASTX) 19% LOWER; according to FDA briefing documents from this morning, a study for dacogen failed to demonstrate benefit based on statistical interpretation.
BioMimetic Therapeutics (Nasdaq: BMTI) 18% HIGHER; as highlighted by a Collins Stewart note this morning, the company announced 6-month results of its 30-patient Canadian Augment Rotator Cuff Graft trial last night. A Collins Stewart analyst called the pilot study positive and said it could create another sizable opportunity for the company.
Coinstar, Inc. (NASDAQ: CSTR) 17.6% HIGHER; reported Q4 EPS of $1.00, $0.36 better than the analyst estimate of $0.64. Revenue for the quarter came in at $520.5 million versus the consensus estimate of $498.09 million. Sees Q1 core EPS of 76-91 cents, which compares to the Street estimate of 86 cents. Sees sales of $530-$555 million, which compares to the Street estimate of $514.5 million. Sees FY12 EPS $3.80-$4.30 on sales of $2.08-$2.25 billion. The Street is currently expecting EPS of $3.86 on sales of $2.17 billion. Also announced it will acquire the assets of NCR's (NYSE: NCR) DVD business. Terms were not disclosed.
Achillion Pharmaceuticals (NASDAQ: ACHN) 16.7% LOWER; BofA/Merrill Lynch downgraded the stock from Buy to Underperform.
McClatchy Co. (NYSE: MNI) 16.5% HIGHER; reported Q4 EPS of $0.49, $0.09 better than the analyst estimate of $0.40. Revenue for the quarter came in at $351.4 million versus the consensus estimate of $347.8 million.
BroadVision (Nasdaq: BVSN) 15.8% LOWER; after rallying nearly 13 percent at the open, the stock tumbled by nearly 30 percent on no apparent news. Volume spiked sharply as downside intensified.
Standard Pacific Corp. (NYSE: SPF) 13.8% HIGHER; reported Q4 EPS of $0.04, $0.02 better than the analyst estimate of $0.02. Revenue for the quarter came in at $293.2 million versus the consensus estimate of $275.21 million.
Cambrex Corp. (NYSE: CBM) 13.7% LOWER; reported Q4 EPS of $0.10, $0.02 worse than the analyst estimate of $0.12. Revenue for the quarter came in at $67.1 million versus the consensus estimate of $64.85 million. Sees FY2012 EBITDA of $47-$53 million. Sees FY2012 revenue of growth of 2-6%, versus the consensus of 5%.
Biosante Pharma (Nasdaq: BPAX) 12.4% LOWER; investors taking profits today following six straight sessions of upside. The stock surged nearly 42 percent yesterday following a bullish SeekingAlpha article. The stock is back under $1 today.
K12, Inc. (NYSE: LRN) 12.3% LOWER; reported Q2 EPS of $0.11, $0.15 worse than the analyst estimate of $0.26. Revenue for the quarter came in at $166.5 million versus the consensus estimate of $170.16 million. K12, Inc. sees FY2012 revenue of $680-$690 million, versus the consensus of $693.4 million.
RTI Int'l Metals, Inc. (NYSE: RTI) 11.6% LOWER; reported Q4 EPS of $0.00, $0.10 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $141.9 million versus the consensus estimate of $137.81 million.
Solarwinds (NYSE: SWI) 10.2% HIGHER; reported Q4 EPS of $0.29, $0.04 better than the analyst estimate of $0.25. Revenue for the quarter came in at $55.6 million versus the consensus estimate of $53.87 million. Sees Q1 2012 EPS of $0.24-$0.25, versus the consensus of $0.25. Sees Q1 2012 revenue of $55.5-$56.7 million, versus the consensus of $54.44 million. Sees FY2012 EPS of $1.10-$1.15, versus the consensus of $1.13. Sees FY2012 revenue of $245-$255 million, versus the consensus of $242.96 million.
Regal-Beloit Corp. (NYSE: RBC) 9.9% HIGHER; reported Q4 EPS of $0.93, $0.23 better than the analyst estimate of $0.70. Revenue for the quarter came in at $727 million versus the consensus estimate of $721.59 million.
Vishay Intertechnology, Inc. (NYSE: VSH) 9.9% LOWER; reported Q4 EPS of $0.15, $0.04 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $551 million versus the consensus estimate of $570.63 million. For Q1, Vishay sees similar revenues as in quarter four 2011 at a slightly improved gross margin.
Threshold Pharma (Nasdaq: THLD) 9.8% LOWER; traders finally taking profits following a 130 percent rise on Friday and another 13 percent surge yesterday. The stock jumped following news of a TH-302 commercialization agreement with Merck.
PHH Corp. (NYSE: PHH) 9% HIGHER; reported Q4 core EPS of $0.98, $0.25 better than the analyst estimate of $0.73. Revenue for the quarter came in at $649 million versus the consensus estimate of $684.7 million.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Merrill Lynch, Bank of America, Collins Stewart, Morning MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
